Healthcare provider profile · identity verified

Martin J Ryan, MD

Internal Medicine · CLEVELAND, OH · NPI 1831203629

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1105	271
Amlodipine Besylate	Amlodipine Besylate	819	222
Losartan Potassium	Losartan Potassium	372	97
Metoprolol Succinate	Metoprolol Succinate	319	81
Lisinopril	Lisinopril	315	90
Hydrochlorothiazide	Hydrochlorothiazide	311	81
Gabapentin	Gabapentin	288	51
Omeprazole	Omeprazole	285	73
Albuterol Sulfate Hfa	Albuterol Sulfate	258	67
Levothyroxine Sodium	Levothyroxine Sodium	229	50
Metformin Hcl Er	Metformin Hcl	206	48
Allopurinol	Allopurinol	200	51
Tamsulosin Hcl	Tamsulosin Hcl	186	55
Metformin Hcl	Metformin Hcl	161	43
Fluticasone Propionate	Fluticasone Propionate	138	41
Rosuvastatin Calcium	Rosuvastatin Calcium	137	48
Metoprolol Tartrate	Metoprolol Tartrate	135	30
Famotidine	Famotidine	122	32
Furosemide	Furosemide	108	30
Carvedilol	Carvedilol	104	29
Pantoprazole Sodium	Pantoprazole Sodium	87	22
Trazodone Hcl	Trazodone Hcl	80	15
Hydralazine Hcl	Hydralazine Hcl	78	25
Ozempic	Semaglutide	76	15
Trulicity	Dulaglutide	75	17
Tramadol Hcl	Tramadol Hcl	74	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	74	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	73	20
Clopidogrel	Clopidogrel Bisulfate	71	19
Diclofenac Sodium	Diclofenac Sodium	71	20
Pravastatin Sodium	Pravastatin Sodium	71	21
Montelukast Sodium	Montelukast Sodium	67	14
Simvastatin	Simvastatin	66	17
Ezetimibe	Ezetimibe	65	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	64	16
Glipizide	Glipizide	64	12
Glimepiride	Glimepiride	63	16
Potassium Chloride	Potassium Chloride	58	22
Tradjenta	Linagliptin	57	13
Hydrocortisone	Hydrocortisone	56	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	52	suppressed
Tizanidine Hcl	Tizanidine Hcl	50	15
Jardiance	Empagliflozin	47	18
Lidocaine	Lidocaine	46	12
Fluoxetine Hcl	Fluoxetine Hcl	44	suppressed
Xarelto	Rivaroxaban	41	11
Farxiga	Dapagliflozin Propanediol	40	suppressed
Sertraline Hcl	Sertraline Hcl	40	suppressed
Spironolactone	Spironolactone	39	13
Triamcinolone Acetonide	Triamcinolone Acetonide	37	16
Finasteride	Finasteride	36	14
Fluocinonide	Fluocinonide	35	12
Ketoconazole	Ketoconazole	35	suppressed
Januvia	Sitagliptin Phosphate	34	suppressed
Baclofen	Baclofen	33	suppressed
Meloxicam	Meloxicam	33	suppressed
Symbicort	Budesonide/Formoterol Fumarate	33	suppressed
Valsartan	Valsartan	33	suppressed
Eliquis	Apixaban	32	suppressed
Pregabalin	Pregabalin	32	suppressed
Azelastine Hcl	Azelastine Hcl	31	11
Peg-3350 And Electrolytes	Peg3350/Sod Sulf,bicarb,cl/Kcl	31	30
Torsemide	Torsemide	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Atenolol	Atenolol	28	suppressed
Felodipine Er	Felodipine	28	suppressed
Ventolin Hfa	Albuterol Sulfate	28	suppressed
Memantine Hcl	Memantine Hcl	27	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	26	suppressed
Ibuprofen	Ibuprofen	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Colchicine	Colchicine	25	suppressed
Loperamide	Loperamide Hcl	24	suppressed
Gavilyte-G	Peg3350/Sod Sulf,bicarb,cl/Kcl	23	22
Advair Diskus	Fluticasone Propion/Salmeterol	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Naproxen	Naproxen	20	suppressed
Spiriva Handihaler	Tiotropium Bromide	20	suppressed
Cilostazol	Cilostazol	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Ammonium Lactate	Ammonium Lactate	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Nystop	Nystatin	15	suppressed
Prednisone	Prednisone	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Trospium Chloride	Trospium Chloride	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Amoxicillin	Amoxicillin	12	12
Methadone Hcl	Methadone Hcl	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Nystatin	Nystatin	11	suppressed
Ulticare	Syringe And Needle,insulin,1ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error